|
|
|
|
||
Very Interesting...Rereading the information that has come to light since the announcement of the tender offer, I stumbled across this, which has given me more interest in the acquiring company. An excerpt... "The Impact of New Japan Regenerative Laws on the Buyout As I have discussed in several articles, Japan has recently made a bold initiative to promote regenerative therapies and has already approved two therapies with full reimbursement under this program. These approvals occurred without the need to go through more conventional and expensive Phase III clinical trials. This streamlined approach has certainly opened the eyes of large Japanese pharmaceutical companies and there is little doubt that the new laws played a role in the Ocata acquisition. The Astellas/Ocata transaction could be a harbinger of new deals to come out of Japan as small U.S. stem cell companies provide the regenerative medicine technology to deep pocketed Japanese pharmaceutical companies that can provide the capital and local market experience to gain PMDA approval under the new laws. A full acquisition is not necessarily the route that these stem cell companies will take but most are actively seeking partners with capital to advance clinical pipelines and achieve product approvals." This appears to knock off significant cost, and time to approval, by knocking off the equivalent of the FDA's Ph3. This is a significant, to me at least, argument in favor of the tender. Am I missing something here? Comments welcome. http://seekingalpha.com/article/3678966-astellas-to-acquire-stem-cell-company-ocata-therapeutics-at -90-percent-premium-what-does-it-mean-for-the-stem-cell-sector |
return to message board, top of board |